Home » Business » Manufacturing
Valeant seals US$8.7b eye health deal
Source: Agencies |
May 28, 2013, Tuesday
|
Print Edition
Print Edition
VALEANT Pharmaceuticals International said yesterday it has agreed to acquire eye care company Bausch & Lomb Holdings Inc from Warburg Pincus LLC for US$8.7 billion in cash.
The deal is expected to transform Quebec-based Valeant into a global leader in eye health by strengthening its capabilities in ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments.
The deal, to be financed through debt and equity, will see some US$4.5 billion go to an investor group led by Warburg Pincus LLC, with some US$4.2 billion used to pay down Bausch & Lomb's outstanding debt.
The deal is expected to transform Quebec-based Valeant into a global leader in eye health by strengthening its capabilities in ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments.
The deal, to be financed through debt and equity, will see some US$4.5 billion go to an investor group led by Warburg Pincus LLC, with some US$4.2 billion used to pay down Bausch & Lomb's outstanding debt.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
